HSC Technology Group has received Therapeutic Goods Approval for selling the company’s powerful CardiacSense heart-monitoring watch in Australia and New Zealand.
The Australia/New Zealand first-of-its-kind device includes precise detection of atrial fibrillation by continuous photoplethysmography signal providing an integrative platform end to end solution for hypertension solution for users.
Australia has an estimated 4 million people with hypertension, and with over 60 per cent undetected, it offers physicians and specialists an easy solution to address a ticking issue.
The company said it had garnered significant excitement from the cardiology sector.
“This is the first cost-effective post-treatment solution that will allow ongoing and continuous monitoring for their clients and the opportunity to provide better ongoing health outcomes,” managing director Graham Russell said.
“It demonstrates the flexibility and power of our Talius Platform, which enables sensor data collection, analysis and presentation to the end-user. We see CardiacSense as a natural evolution beyond our existing aged care focus and provides us further entry into the broader healthcare market.”
The company plan to continue focusing on bringing its Internet of Things technology to international markets.
HSC’s Australian Stock Exchange-listed share price was trading at 1.1c today (11: 39 am UTC+ 8 hours).